Products for Research Use Only
RegisterLogin

Minzasolmin

CAT: 0804-HY-145580-01Size: 1 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-145580-01Size:1 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
Minzasolmin (UCB0599; (R) -NPT200-11) is an orally active, blood-brain-permeable α-synuclein (α-Syn) inhibitor that selectively binds to α-Syn misfolded intermediates (such as oligomers) and inhibits aggregation and fibril formation by regulating their conformational stability. Minzasolmin can reduce the generation of pathological oligomers and block neurotoxic signaling, thereby reducing the abnormal accumulation of α-Syn in the brain. Minzasolmin significantly improved motor deficits, reduced neuroinflammatory markers, and α-Syn-related pathological deposition in transgenic mouse models[1][2].
CAS Number
1802518-92-8
Product Name Alternative
UCB0599; (R) -NPT200-11
UNSPSC
12352005
Target
α-synuclein
Type
Reference compound
Related Pathways
Neuronal Signaling
Applications
Neuroscience-Neuromodulation
Field of Research
Neurological Disease
Assay Protocol
https://www.medchemexpress.com/minzasolmin.html
Purity
98.60
Solubility
DMSO : 100 mg/mL (ultrasonic)
Smiles
O=C(C1=CN=C(N2CCN(CC2)C)S1)N[C@H](CCCC)CC3=CNC4=CC=CC=C34
Molecular Formula
C23H31N5OS
Molecular Weight
425.59
References & Citations
[1]Steiner MA. Matters arising: In vivo effects of the alpha-synuclein misfolding inhibitor minzasolmin supports clinical development in Parkinson's disease. NPJ Parkinsons Dis. 2024 Mar 14;10 (1) :59.|[2]Baggett, et al. Novel Approaches Targeting in α-Synuclein for Parkinson's Disease: Current Progress and Future Directions for the Disease-Modifying Therapies. Brain Disorders (2024) : 100163.
Shipping Conditions
Room Temperature
Storage Conditions
4°C (Powder, stored under nitrogen)
Scientific Category
Reference compound1
Clinical Information
Phase 2
Isoform
α-synuclein Aggregation

Chemical Information

Minzasolmin

Minzasolmin is under investigation in clinical trial NCT05543252 (An Extension Study to Evaluate the Long-term Efficacy, Safety and Tolerability of Minzasolmin (UCB0599) in Study Participants With Parkinson's Disease).

CAS Number1802518-92-8
PubChem CID118279413
IUPAC NameN-[(2R)-1-(1H-indol-3-yl)hexan-2-yl]-2-(4-methylpiperazin-1-yl)-1,3-thiazole-5-carboxamide
Molecular FormulaC23H31N5OS
Molecular Weight425.6
XLogP4.8
Topological Polar Surface Area92.5
Hydrogen Bond Donor Count2
Hydrogen Bond Acceptor Count5
Rotatable Bond Count8
Heavy Atom Count30
Formal Charge0
Complexity556
SMILES
CCCC[C@H](CC1=CNC2=CC=CC=C21)NC(=O)C3=CN=C(S3)N4CCN(CC4)C
InChI
InChI=1S/C23H31N5OS/c1-3-4-7-18(14-17-15-24-20-9-6-5-8-19(17)20)26-22(29)21-16-25-23(30-21)28-12-10-27(2)11-13-28/h5-6,8-9,15-16,18,24H,3-4,7,10-14H2,1-2H3,(H,26,29)/t18-/m1/s1
InChIKey
GDFWCSZNQVAQGR-GOSISDBHSA-N
Chemical Structure
2D Structure
2D structure of Minzasolmin
CAS: 1802518-92-8
CID: 118279413
Formula: C23H31N5OS
MW: 425.6
Interactive 3D Structure
Loading 3D structure...
View on PubChemRaw 3D data
Computed Properties
PropertyValue
Molecular Weight425.6
XLogP34.8
Hydrogen Bond Donor Count2
Hydrogen Bond Acceptor Count5
Rotatable Bond Count8
Exact Mass425.22493180
Monoisotopic Mass425.22493180
Topological Polar Surface Area92.5 Ų
Heavy Atom Count30
Formal Charge0
Complexity556
Isotope Atom Count0
Defined Atom Stereocenter Count1
Undefined Atom Stereocenter Count0
Defined Bond Stereocenter Count0
Undefined Bond Stereocenter Count0
Covalently-Bonded Unit Count1
Compound Is CanonicalizedYes

Alternative Products

CatalogName
T62304-01Minzasolmin

Popular Products